teva pharmaceutical-sp adr
(TEVA:New York Consolidated)
Transactions by TEVA PHARMACEUTICAL-SP ADR (TEVA) in the last 6 months
Teva Pharmaceutical Industries Limited (NYSE:TEVA) entered into definitive agreement to acquire Representaciones e Investigaciones Medicas, S.A. de C.V (Rimsa ) for $2.3 billion in a debt-free, cash free deal on October 1, 2015. The transactions will be funded through a combination of cash on hand and lines of credit. Rimsa had revenue in 2014 of $227 million. The acquisition was unanimously approved by Teva's Board of Directors, led by the Chairman, Yitzhak Peterburg. ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA) entered into a definitive agreement to acquire Gecko Health Innovations, Inc. on September 25, 2015. Under the terms, Teva will acquire CareTRx through the agreement.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) entered into an agreement to acquire 51% stake in Immuneering Corporation on August 3, 2015.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) signed a definitive agreement to acquire Allergan Generics from Allergan plc (NYSE:AGN) for $40.5 billion in cash and stock on July 26, 2015. On closing, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion, representing a 10% ownership stake in Teva. Allergan Generics is being acquired as cash free and debt free basis. Teva will pay Allergan $33.75 billion in cash which will ...
ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) acquired 22 generic drug products from Teva Pharmaceutical Industries Limited (NYSE:TEVA) for $25 million on July 10, 2015. ANI Pharmaceuticals will pay $25 million in cash and a percentage of future gross profits from product sales. The acquisition is being funded through cash on hand.
Microchips Biotech, Inc. announced that it will receive $18,648,546 in funding on June 17, 2015. The company will issue common stock in the transaction. The transaction will include participation from five investors. The company will issue securities pursuant to exemption provided under Regulation D.
On June 18, 2015, the company amended the terms of the transaction. The company announced that it has entered in to an agreement to receive $35,000,000 in an equity funding ...
American Well Corporation announced that it will receive tens of millions of dollars funding from new investor, Teva Pharmaceutical Industries Limited on June 2, 2015.
Soros Fund Management LLC sold all of its 0.6% stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the first quarter of 2015. Soros Fund Management sold all the 4.9 million shares of Teva held by it.
ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) acquired New Drug Application for Testosterone Gel from Teva Pharmaceutical Industries Limited (NYSE:TEVA) for $5 million on May 13, 2015. Upon commercialization, ANI will pay Teva up to $5 million at a rate of 5% of the consideration received by ANI as a result of commercial sale of the product.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) made a proposal to acquire Mylan N.V. (NasdaqGS:MYL) for $31 billion on April 21, 2015. Teva offered $82 a share in cash and stock for Mylan. The consideration would comprise of approximately 50% cash and 50% stock. The proposal was unanimously approved by the Board of Directors of Teva. This proposal is subject to customary conditions. The transaction would not be subject to a financing condition or require a Teva stockholder ...
|Abbott Laboratories||$39.89 USD||-1.50|
|AbbVie Inc||$55.08 USD||-1.60|
|AstraZeneca PLC||4,134 GBp||-67.50|
|Biogen Inc||$275.99 USD||-10.56|
|Eli Lilly & Co||$84.17 USD||-2.40|
|View Industry Companies|